SFX by Ex Libris Inc.

Title:	Rapid Identification of a Novel Small Molecule Phosphodiesterase 10A (PDE10A) Tracer
Source:	Journal of Medicinal Chemistry [0022-2623] Hu, Essa yr:2012

Basic

Full text

Full text available via American Chemical Society Journals

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Kuang, R. "Discovery of oxazole-based PDE4 inhibitors with picomolar potency." Bioorganic and medicinal chemistry letters 22.7 (2012): 2594-2597.
description	2.	Jager, R. "Activation of PDE10 and PDE11 Phosphodiesterases." Journal of biological chemistry 287.2 (2012): 1210-1219.
description	3.	Nichols DE, Frescas SP, Chemel BR, Rehder KS, Zhon, D. "High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): A high-affinity 5-HT(2A) receptor-selective agonist radioligand." Bioorganic & medicinal chemistry 16.11: 6116-6123.
description	4.	Parker, M.A. A. "The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands." Bioorganic & medicinal chemistry 16.8 (2008): 4661-4669.
description	5.	Matthiesen, K. "Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity." Biochemical journal 423.3 (2009): 401-409.
description	6.	Chalimoniuk, M. "Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice." Biochemical and biophysical research communications 324.1 (2004): 118-126.
description	7.	Siuciak, J. "Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia." Expert opinion on drug discovery 2.7 (2007): 1001-1009.
description	8.	Jaeger, R. "Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5." British Journal of Pharmacology 161.7 (2010): 1645-1660.
description	9.	Xu, J. "Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors." Bioorganic & medicinal chemistry letters 16.20: 5373-7.
description	10.	O'Donnell, James M M. "Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B, -4B, and -10A expression in rat striatum." Neuropharmacology 54.4 (2008): 745-54.
description	11.	Chambers, James J. "Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT2A/2C receptor affinity." Bioorganic & medicinal chemistry letters 12.15 (2002): 1997-1999.
description	12.	Nagai, F. "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain." European Journal of Pharmacology 559.2-3 (2007): 132-7.
description	13.	Ley, Rachel N. "Catalytic polymer-supported potassium thiophenolate in methanol as a method for the removal of ester, amide, and thioacetate protecting groups." Synlett 4 (2004): 675-678.
description	14.	Gorobets, E. "Synthesis, resolution and applications of 3,3'-bis(RO)-MeO-BIPHEP derivatives." Tetrahedron letters 45.18 (2004): 3597-3601.
description	15.	"Discovery of orally active, potent, and selective benzotriazole-based PTP1B inhibitors." ChemMedChem. 6.6: 1011-1016.
description	16.	Owen, Stewart F F. "Comparative physiology, pharmacology and toxicology of beta-blockers: mammals versus fish." Aquatic Toxicology 82.3 (2007): 145-62.
description	17.	Schultz, Danielle M. "‘Hybrid’benzofuran–benzopyran congeners as rigid analogs of hallucinogenic phenethylamines." Bioorganic & medicinal chemistry 16.11 (2008): 6242-6251.
description	18.	Crouch, R. d. "Removal of acyl protecting groups using solid NaOH and a phase transfer catalyst." Synlett 7 (2003): 991-992.
description	19.	Van Veldhuizen, J. "Chiral Ru-based complexes for asymmetric olefin metathesis: Enhancement of catalyst activity through steric and electronic modifications." Journal of the American Chemical Society 125.41 (2003): 12502-12508.
description	20.	Horácek, V. "Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose." Psychopharmacology 196.1 (2007): 51-62.